The United Laboratories International Holdings Limited logo

The United Laboratories International Holdings Limited

3933.HK

HKSEHealthcareDrug Manufacturers - Specialty & Generic

Latest quote

HK$8.95

−HK$0.06 · -0.67%

Aug 24, 4:08 PM HKT

3933.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, from pioneering research and development to manufacturing, distribution, and sales. The company structures its diverse business into three core divisions: Bulk Medicine, Intermediate Products, and Finished Goods. Its broad product portfolio features a variety of medications, such as oral antibiotics, injectable antimicrobials, cold and cough remedies, ophthalmic solutions, antiviral and anti-hepatitis B drugs, diabetes treatments, topical dermatological preparations, cardiovascular and neurological pharmaceuticals, vitamins, and empty gelatin capsules, alongside active pharmaceutical ingredients (APIs) and other intermediary compounds. Furthermore, the company manufactures and markets soft capsule shells, holds trademarks, engages in pharmaceutical trading, and provides management services. Founded in 1990 and headquartered in Yuen Long, Hong Kong, the firm maintains a significant global reach, conducting business throughout the People's Republic of China, Europe, India, the Middle East, South America, other Asian territories, and internationally.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
HK
CEO
Hoi Shan Tsoi
Listed since
Jun 15, 2007
Employees
18,000

Market position

52-week range

Current HK$8.95

Open
HK$8.95
Previous close
HK$9.01
Volume
10M
1.33× average
Average volume
7.53M
Average daily volume
Market cap
17.63B HKD
Beta
0.3
Market reference 1
50-day average
HK$8.9079
+0.47% above average
200-day average
HK$10.6374
-15.86% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
13.38B CNY
P/E (TTM)
6.75×
P/B (TTM)
0.86×
P/S (TTM)
1.15×
EV / EBITDA
4.72×
Earnings yield
10.63%
Free cash flow yield
4.36%
Dividend yield
3.34%

Profitability & efficiency

Gross margin
41.74%
Operating margin
17.21%
Net margin
15.79%
Return on equity
11.99%
Return on assets
6.75%
Return on invested capital
8.15%

Financial health

Debt / equity
0.29×
Current ratio
1.83×
Altman Z-score
2.84
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends50%35%21%7%Gross margin, FY2021: 43.40%Gross margin, FY2022: 43.84%Gross margin, FY2023: 46.11%Gross margin, FY2024: 44.21%Gross margin, FY2025: 41.74%Operating margin, FY2021: 14.55%Operating margin, FY2022: 17.78%Operating margin, FY2023: 23.94%Operating margin, FY2024: 22.65%Operating margin, FY2025: 17.20%Net margin, FY2021: 10.18%Net margin, FY2022: 13.95%Net margin, FY2023: 19.66%Net margin, FY2024: 19.33%Net margin, FY2025: 15.79%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 43.40%. Gross margin FY2022 43.84%. Gross margin FY2023 46.11%. Gross margin FY2024 44.21%. Gross margin FY2025 41.74%. Operating margin FY2021 14.55%. Operating margin FY2022 17.78%. Operating margin FY2023 23.94%. Operating margin FY2024 22.65%. Operating margin FY2025 17.20%. Net margin FY2021 10.18%. Net margin FY2022 13.95%. Net margin FY2023 19.66%. Net margin FY2024 19.33%. Net margin FY2025 15.79%.

Income trends

Revenue

13.21B CNY-3.99%

Operating income

2.27B CNY-27.10%

Net income

2.09B CNY-21.57%
Income trends across reported periods15.04B CNY9.93B CNY4.82B CNY−288.99M CNYRevenue, FY2021: 9.7B CNYRevenue, FY2022: 11.33B CNYRevenue, FY2023: 13.74B CNYRevenue, FY2024: 13.76B CNYRevenue, FY2025: 13.21B CNYOperating income, FY2021: 1.41B CNYOperating income, FY2022: 2.02B CNYOperating income, FY2023: 3.29B CNYOperating income, FY2024: 3.12B CNYOperating income, FY2025: 2.27B CNYNet income, FY2021: 988.1M CNYNet income, FY2022: 1.58B CNYNet income, FY2023: 2.7B CNYNet income, FY2024: 2.66B CNYNet income, FY2025: 2.09B CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.7B CNY. Revenue FY2022 11.33B CNY. Revenue FY2023 13.74B CNY. Revenue FY2024 13.76B CNY. Revenue FY2025 13.21B CNY. Operating income FY2021 1.41B CNY. Operating income FY2022 2.02B CNY. Operating income FY2023 3.29B CNY. Operating income FY2024 3.12B CNY. Operating income FY2025 2.27B CNY. Net income FY2021 988.1M CNY. Net income FY2022 1.58B CNY. Net income FY2023 2.7B CNY. Net income FY2024 2.66B CNY. Net income FY2025 2.09B CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue13.21B CNY13.76B CNY13.74B CNY11.33B CNY9.7B CNY
Cost of goods sold7.7B CNY7.68B CNY7.41B CNY6.37B CNY5.49B CNY
Gross profit5.51B CNY6.08B CNY6.33B CNY4.97B CNY4.21B CNY
Research and development921.05M CNY890.76M CNY757.25M CNY593.6M CNY465.24M CNY
Selling, general, and administrative2.3B CNY2.3B CNY2.38B CNY2.37B CNY2.33B CNY
Operating expenses3.24B CNY3.23B CNY3.05B CNY2.95B CNY2.8B CNY
Interest income152.57M CNY127.79M CNY105.42M CNY70.74M CNY82.78M CNY
Interest expense69.73M CNY34.96M CNY66.9M CNY81.6M CNY60.23M CNY
Depreciation and amortization613.21M CNY538.01M CNY565.65M CNY523.67M CNY596.06M CNY
Operating income2.27B CNY3.12B CNY3.29B CNY2.02B CNY1.41B CNY
Net income2.09B CNY2.66B CNY2.7B CNY1.58B CNY988.1M CNY

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+23.58%
11 comparable reports
Latest EPS result
0.12
Estimate 0.07 · Beat by 83.32%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates1.571.070.560.06Q4 '22BeatQ2 '23BeatQ4 '23BeatQ2 '24BeatQ4 '24MissQ3 '25MissQ1 '26BeatQ3 '26Estimate
Q4 2022, reported Dec 31, 2022: actual 0.596, estimate 0.317, surprise +88.01%, Beat. Q2 2023, reported Jun 30, 2023: actual 0.764, estimate 0.378, surprise +102.01%, Beat. Q4 2023, reported Dec 31, 2023: actual 0.863, estimate 0.803, surprise +7.47%, Beat. Q2 2024, reported Jun 30, 2024: actual 0.881, estimate 0.817, surprise +7.83%, Beat. Q4 2024, reported Dec 31, 2024: actual 0.684, estimate 0.83, surprise -17.59%, Miss. Q3 2025, reported Sep 1, 2025: actual 1.14, estimate 1.46, surprise -21.92%, Miss. Q1 2026, reported Mar 24, 2026: actual 0.122, estimate 0.067, surprise +83.32%, Beat. Q3 2026, reported Aug 31, 2026: actual —, estimate 0.15, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates9B7.8B6.6B5.41BQ4 '22BeatQ2 '23BeatQ4 '23MissQ2 '24MissQ4 '24MissQ3 '25MissQ1 '26BeatQ3 '26Estimate
Q4 2022, reported Dec 31, 2022: actual 7.01B HKD, estimate 5.94B HKD, surprise +17.99%, Beat. Q2 2023, reported Jun 30, 2023: actual 7.47B HKD, estimate 5.86B HKD, surprise +27.53%, Beat. Q4 2023, reported Dec 31, 2023: actual 7.56B HKD, estimate 7.66B HKD, surprise -1.29%, Miss. Q2 2024, reported Jun 30, 2024: actual 7.71B HKD, estimate 7.82B HKD, surprise -1.46%, Miss. Q4 2024, reported Dec 31, 2024: actual 7B HKD, estimate 7.98B HKD, surprise -12.28%, Miss. Q3 2025, reported Sep 1, 2025: actual 8.23B HKD, estimate 8.66B HKD, surprise -4.96%, Miss. Q1 2026, reported Mar 24, 2026: actual 6.33B HKD, estimate 5.75B HKD, surprise +10.12%, Beat. Q3 2026, reported Aug 31, 2026: actual —, estimate 6.42B HKD, surprise —, Comparison unavailable.

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

HK$0.5693

2025 complete year+292.8% since 2021

2026 partial: HK$0.299

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Jul 7, 2026

HK$0.299

Annual

Record Jul 8, 2026 · Payment Jul 22, 2026

Dividend

Ex-dividend Sep 25, 2025

HK$0.1751

Annual

Record Sep 26, 2025 · Payment Oct 15, 2025

Dividend

Ex-dividend Jul 8, 2025

HK$0.3942

Special

Record Jul 9, 2025 · Payment Jul 23, 2025

Dividend

Ex-dividend Sep 19, 2024

HK$0.1763

Annual

Record Sep 20, 2024 · Payment Oct 15, 2024

Dividend

Ex-dividend Jul 2, 2024

HK$0.439

Special

Record Jul 3, 2024 · Payment Jul 24, 2024

Dividend

Ex-dividend Sep 14, 2023

HK$0.1307

Annual

Record Sep 15, 2023 · Payment Oct 11, 2023

3933.HK peers

ETFs holding 3933.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 3933.HK

research.disclaimer